Peptide HRH acetate
Based on 1 Customer Validation
Peptide HRH acetate is a polypeptide that specifically binds to VEGF receptors. Peptide HRH acetate inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH acetate inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH acetate can be used in anti-angiogenesis related studies.
For research use only. We do not sell to patients.
- Purity: 97.16%
- Formula: C64H104N28O16·xC2H4O2
- Molecular Weight:1521.69 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
Peptide HRH (0.95-3.85 μg/μL; 96 h) acetate dose-dependently inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells (HUVECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human umbilical vein endothelial cells (HUVECs) stimulated with VEGF
-
Concentration:0.95; 1.9; 3.85 μg/μL
-
Incubation Time:96 h
-
Result:Suppressed the proliferation of VEGF-stimulated HUVECs in a dose-dependent manner.
Peptide HRH (10 μg/μL; topical eye drops; four times per day; 14 days) acetate significantly inhibits corneal neovascularization in the alkali-burned rat corneal model[1].
Peptide HRH (10 μg/μL; topical eye drops; four times per day; 14 days) acetate significantly inhibits corneal neovascularization in the suture-induced rat corneal model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, alkali-burned corneal model)[1]
-
Dosage:10 μg/μL
-
Administration:topical eye drops; four times per day; 14 days
-
Result:Significantly reduced corneal neovascularization area from days 3 to 14 post-burn.
Kept most of the corneal stroma free of blood vessels.
-
Animal Model:Sprague-Dawley (male, suture-induced corneal model)[1]
-
Dosage:10 μg/μL
-
Administration:topical eye drops; four times per day; 14 days
-
Result:Significantly reduced maximum vessel length and total corneal neovascularization area from days 3 to 14 post-suture.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1521.69 (free base)
-
Formula C64H104N28O16·xC2H4O2
-
Color White to off-white
-
Sequence
His-Arg-His-Thr-Lys-Gln-Arg-His-Thr-Ala-Leu-His
-
Sequence Shortening
HRHTKQRHTALH
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 100 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peptide HRH acetate Related Classifications
HY-P11775A Related Classifications
Powered by Bioz